Pharmaceutical Executive
Flashpoint Medica's "Little girl, big shoes" campaign was used to portray the problem of central precocious puberty for the launch of Supprelin LA from Indevus Pharmaceuticals.
LITTLE GIRL, BIG SHOES
Flashpoint Medica
BRAND Supprelin LA CLIENT Indevus Pharmaceuticals FROM LEFT: Steve Frederick, evp, creative director; Shannon Fitzgerald, senior account executive; Helen Appelbaum, partner, chief operating officer; Kerry Baker, svp, associate creative director
Flashpoint Medica's "Little girl, big shoes" campaign was used to portray the problem of central precocious puberty for the launch of Supprelin LA from Indevus Pharmaceuticals. Little girls often play "dress up," but this condition makes them grow up too quickly. The marketing challenge was to convince physicians that a once-yearly implant to suppress hormones was preferred to painful monthly injections.
The series of feet-focused ads captures the essence of childhood freedom and playfulness, while conveying the message that Supprelin LA provides "a year of nonstop childhood." From a branding perspective, the strong use of the color pink conveyed that the condition primarily affects young girls.
"In pediatrician journals, you see a lot of faces. We wanted to stand out," says Steve Frederick, executive vice president, creative director. "Our whole imagery was centered on driving home the sense of freedom that a child feels when partaking in different activities."
The campaign has resonated with healthcare professionals and parents of children with this condition, as well as other key stakeholders and Indevus sales reps.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.